Cargando…

Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis

INTRODUCTION: Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (M.TB) and other species of the Mycobacterium tuberculosis complex. Globally, TB is ranked as the ninth leading cause of death and the leading cause of death from a single infectious agent. The bacille Calmette-Guerin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahasha, Phetole Walter, Ndwandwe, Duduzile Edith, Mavundza, Edison Johannes, Shey, Muki, Wiysonge, Charles Shey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797475/
https://www.ncbi.nlm.nih.gov/pubmed/31619416
http://dx.doi.org/10.1136/bmjopen-2018-027033
_version_ 1783459837372268544
author Mahasha, Phetole Walter
Ndwandwe, Duduzile Edith
Mavundza, Edison Johannes
Shey, Muki
Wiysonge, Charles Shey
author_facet Mahasha, Phetole Walter
Ndwandwe, Duduzile Edith
Mavundza, Edison Johannes
Shey, Muki
Wiysonge, Charles Shey
author_sort Mahasha, Phetole Walter
collection PubMed
description INTRODUCTION: Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (M.TB) and other species of the Mycobacterium tuberculosis complex. Globally, TB is ranked as the ninth leading cause of death and the leading cause of death from a single infectious agent. The bacille Calmette-Guerin (BCG) vaccine has been used globally since 1921 for the prevention of TB in humans, and was derived from an attenuated strain of Mycobacterium bovis. Evidence from previous randomised trials show that the efficacy of primary BCG vaccination against pulmonary TB ranged from no protection to very high protection. In addition, some studies suggest a benefit of BCG revaccination. For example, a recent trial conducted in South Africa showed that BCG revaccination of adolescents could reduce the risk of TB infection by half. However, we are not aware of any recent systematic reviews of the effects of BCG revaccination. Thus, the need for this systematic review of the effects of BCG revaccination on protection against TB infection and disease. METHOD AND ANALYSIS: We will search PubMed, the Cochrane Central Register of Controlled Trials, EMBASE, WHO International Clinical Trials Registry Platform and reference lists of relevant publications for potentially eligible studies. We will screen search outputs, select eligible studies, extract data and assess risk of bias in duplicate. Discrepancies will be resolved by discussion and consensus or arbitration. We will use the Grading of Recommendations Assessment, Development and Evaluation method to assess the certainty of the evidence. The planned systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) in August 2018. ETHICS AND DISSEMINATION: Publicly available data will be used, hence no formal ethical approval will be required for this review. The findings of the review will be disseminated through conference presentations and publication in an open-access peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42018105916
format Online
Article
Text
id pubmed-6797475
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-67974752019-11-01 Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis Mahasha, Phetole Walter Ndwandwe, Duduzile Edith Mavundza, Edison Johannes Shey, Muki Wiysonge, Charles Shey BMJ Open Public Health INTRODUCTION: Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (M.TB) and other species of the Mycobacterium tuberculosis complex. Globally, TB is ranked as the ninth leading cause of death and the leading cause of death from a single infectious agent. The bacille Calmette-Guerin (BCG) vaccine has been used globally since 1921 for the prevention of TB in humans, and was derived from an attenuated strain of Mycobacterium bovis. Evidence from previous randomised trials show that the efficacy of primary BCG vaccination against pulmonary TB ranged from no protection to very high protection. In addition, some studies suggest a benefit of BCG revaccination. For example, a recent trial conducted in South Africa showed that BCG revaccination of adolescents could reduce the risk of TB infection by half. However, we are not aware of any recent systematic reviews of the effects of BCG revaccination. Thus, the need for this systematic review of the effects of BCG revaccination on protection against TB infection and disease. METHOD AND ANALYSIS: We will search PubMed, the Cochrane Central Register of Controlled Trials, EMBASE, WHO International Clinical Trials Registry Platform and reference lists of relevant publications for potentially eligible studies. We will screen search outputs, select eligible studies, extract data and assess risk of bias in duplicate. Discrepancies will be resolved by discussion and consensus or arbitration. We will use the Grading of Recommendations Assessment, Development and Evaluation method to assess the certainty of the evidence. The planned systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) in August 2018. ETHICS AND DISSEMINATION: Publicly available data will be used, hence no formal ethical approval will be required for this review. The findings of the review will be disseminated through conference presentations and publication in an open-access peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42018105916 BMJ Publishing Group 2019-10-15 /pmc/articles/PMC6797475/ /pubmed/31619416 http://dx.doi.org/10.1136/bmjopen-2018-027033 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Public Health
Mahasha, Phetole Walter
Ndwandwe, Duduzile Edith
Mavundza, Edison Johannes
Shey, Muki
Wiysonge, Charles Shey
Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
title Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
title_full Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
title_fullStr Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
title_full_unstemmed Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
title_short Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis
title_sort systematic review protocol on bacillus calmette-guerin (bcg) revaccination and protection against tuberculosis
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797475/
https://www.ncbi.nlm.nih.gov/pubmed/31619416
http://dx.doi.org/10.1136/bmjopen-2018-027033
work_keys_str_mv AT mahashaphetolewalter systematicreviewprotocolonbacilluscalmetteguerinbcgrevaccinationandprotectionagainsttuberculosis
AT ndwandweduduzileedith systematicreviewprotocolonbacilluscalmetteguerinbcgrevaccinationandprotectionagainsttuberculosis
AT mavundzaedisonjohannes systematicreviewprotocolonbacilluscalmetteguerinbcgrevaccinationandprotectionagainsttuberculosis
AT sheymuki systematicreviewprotocolonbacilluscalmetteguerinbcgrevaccinationandprotectionagainsttuberculosis
AT wiysongecharlesshey systematicreviewprotocolonbacilluscalmetteguerinbcgrevaccinationandprotectionagainsttuberculosis